Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDTravere Therapeutics Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 6 | -$0.49 | $0.12 | -$0.24 |
| Q2 2026 | 6 | -$0.16 | $0.01 | -$0.06 |
| Q3 2026 | 6 | $0.04 | $0.13 | $0.09 |
| Q4 2026 | 4 | $0.44 | $0.68 | $0.53 |
| Q1 2027 | 2 | $0.27 | $0.41 | $0.32 |
| Q2 2027 | 2 | $0.40 | $0.61 | $0.48 |
| Q3 2027 | 2 | $0.52 | $0.80 | $0.63 |
| Q4 2027 | 2 | $0.73 | $1.12 | $0.88 |
Travere Therapeutics Inc Earnings Date And Information
Travere Therapeutics Inc last posted its earnings results on Monday, May 4th, 2026. The company reported $-0.39 earnings per share for the quarter, missing analysts' consensus estimates of $-0.24203 by $0.14797. The company had revenue of 127.20 M for the quarter and had revenue of 490.73 M for the year. Travere Therapeutics Inc has generated $-1 earnings per share over the last year ($-0.56 diluted earnings per share) and currently has a price-to-earnings ratio of -88.34. Travere Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Travere Therapeutics Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/04/2026 | Q1 2026 | -$0.24 | -$0.40 | -0.16 | $136.23 M | $127.20 M |
| 02/19/2026 | Q4 2025 | $0.03 | -$0.24 | -0.27 | $144.55 M | $129.69 M |
| 10/30/2025 | Q3 2025 | -$0.31 | $0.29 | 0.6 | $105.21 M | $164.86 M |
| 08/06/2025 | Q2 2025 | -$0.28 | -$0.14 | 0.14 | $99.47 M | $114.45 M |
| 05/01/2025 | Q1 2025 | -$0.55 | -$0.47 | 0.08 | $77.27 M | $81.73 M |
| 02/20/2025 | Q4 2024 | N/A | -$0.73 | N/A | $73.08 M | $74.79 M |
| 10/31/2024 | Q3 2024 | -$0.70 | -$0.70 | 0 | $60.87 M | $62.90 M |
| 08/01/2024 | Q2 2024 | -$0.87 | -$0.91 | -0.04 | $50.40 M | $54.12 M |
| 05/06/2024 | Q1 2024 | -$0.98 | -$1.76 | -0.78 | $43.46 M | $41.37 M |
| 02/20/2024 | Q4 2023 | N/A | -$1.18 | N/A | N/A | $45.06 M |
| 11/07/2023 | Q3 2023 | -$1.09 | -$0.99 | 0.1 | N/A | $37.10 M |
| 08/03/2023 | Q2 2023 | -$1.16 | -$1.13 | 0.03 | N/A | $32.20 M |
| 05/04/2023 | Q1 2023 | -$1.18 | -$1.27 | -0.09 | N/A | $56.99 M |
| 02/23/2023 | Q4 2022 | -$1.04 | -$1.03 | 0.01 | N/A | $55.87 M |
| 10/27/2022 | Q3 2022 | -$0.97 | -$1.09 | -0.12 | N/A | $28.08 M |
| 08/04/2022 | Q2 2022 | -$0.94 | -$1.05 | -0.11 | N/A | $54.17 M |
| 05/05/2022 | Q1 2022 | -$0.85 | -$1.20 | -0.35 | N/A | $48.49 M |
| 02/24/2022 | Q4 2021 | -$0.72 | -$0.84 | -0.12 | N/A | $57.25 M |
| 10/28/2021 | Q3 2021 | N/A | -$0.59 | N/A | N/A | $68.22 M |
| 07/29/2021 | Q2 2021 | -$0.73 | -$0.64 | 0.09 | N/A | $54.62 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Travere Therapeutics Inc Earnings: FAQ's
The conference call for Travere Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for Travere Therapeutics Inc's latest earnings report can be read online.
Travere Therapeutics Inc (:TVTX) has a recorded annual revenue of $490.73 M.
Travere Therapeutics Inc (:TVTX) has a recorded net income of $-25,546,000.Travere Therapeutics Inc has generated $-0.56 earnings per share over the last four quarters.
Travere Therapeutics Inc (:TVTX) has a price-to-earnings ratio of -88.34 and price/earnings-to-growth ratio is -0.42.